Oral tegafur in the treatment of gastrointestinal tract cancers: a phase II study.

Fifty patients affected by histologically confirmed gastrointestinal tract cancer (GTC) were treated with oral tegafur (TG) 1,000 mg m-2 p.o. on days 1-14 repeated after a 14 day interval. Out of 42 evaluable patients seven patients had a partial response (PR. 17%) with a median duration of 20.5 wee...

Descripción completa

Detalles Bibliográficos
Autores principales: Palmeri, S., Gebbia, V., Russo, A., Armata, M. G., Gebbia, N., Rausa, L.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1990
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971297/
https://www.ncbi.nlm.nih.gov/pubmed/2109630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971297/
https://www.ncbi.nlm.nih.gov/pubmed/2109630

Ejemplares similares